Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 13 2024
0mins
Source: NASDAQ.COM
Overview of Vident International Equity Strategy ETF (VIDI): Launched in 2013, VIDI is a smart beta ETF that aims to outperform the World ETFs segment by utilizing a principles-based selection strategy and balancing risk across developed and emerging markets, with an expense ratio of 0.61% and a 12-month dividend yield of 3.50%.
Comparison with Other ETFs: While VIDI has shown positive performance, investors may also consider lower-cost traditional market cap weighted ETFs like Vanguard Total International Stock ETF (VXUS) and Vanguard FTSE Developed Markets ETF (VEA), which have significantly lower expense ratios and larger asset bases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JAZZ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to fall
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 226.880
Low
188.00
Averages
218.92
High
263.00
Current: 226.880
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jazz Pharmaceuticals Q1 Earnings Analysis and Investment Recommendations
- Strong Stock Performance: Jazz Pharmaceuticals' stock has risen 37.1% over the past six months, currently trading at $232.44, outperforming the S&P 500 by 28.7%, indicating market recognition of its short-term performance, yet long-term growth potential remains questionable.
- Lackluster Revenue Growth: The company’s annualized revenue growth of 7.5% over the past two years falls short of its five-year trend, suggesting a slowdown in demand that may reflect changing consumer preferences, thereby increasing investment risks.
- Declining Adjusted Operating Margin: Jazz's adjusted operating margin has decreased by 21.5 percentage points over the last five years, currently at 22.4%, raising concerns about its cost structure and failing to achieve expected economies of scale.
- EPS Decline: Despite an 11.7% revenue growth, the company's earnings per share (EPS) has declined by 4.2% annually over the past five years, indicating a weakening profitability per share during its expansion, prompting investors to carefully assess its future earnings potential.
See More
Jazz Pharmaceuticals Unveils New Research Advances at SLEEP 2026
- New Research Findings: Jazz Pharmaceuticals presented 11 late-breaking studies at SLEEP 2026, highlighting Xywav®'s significant efficacy in treating narcolepsy and idiopathic hypersomnia, particularly in improving cardiometabolic risk markers, underscoring the drug's importance in patient health management.
- Personalized Treatment Plans: The research indicates that Xywav's individualized dosing adjustments can be optimized based on patient tolerability and efficacy, with data showing an average time to reach a stable dose of 42.1 days for idiopathic hypersomnia and 41.8 days for narcolepsy, demonstrating the feasibility and effectiveness of personalized treatment.
- Long-term Benefits of Low-Sodium Formulation: New data showcases that Xywav's low-sodium formulation not only alleviates core symptoms but also positively impacts long-term cardiovascular health, with patients reporting significant decreases in cardiovascular risk markers such as non-HDL cholesterol and triglycerides after switching to Xywav, highlighting the clinical benefits of sodium reduction.
- Ongoing Scientific Advancement: Jazz Pharmaceuticals' research team continues to advance the scientific understanding of these rare sleep disorders, emphasizing Xywav's potential to improve patient quality of life and reshape treatment paradigms.
See More
Jazz Pharmaceuticals and AbCellera Collaborate on Antibody Development
- Collaboration Overview: Jazz Pharmaceuticals has entered into a research collaboration and license agreement with AbCellera Biologics to develop next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and other solid tumors, leveraging Jazz's oncology expertise and AbCellera's antibody discovery platform.
- Financial Terms: Under the agreement, AbCellera will receive $56 million in upfront payments for the first two programs and an additional $28 million upon the initiation of the third program, with potential milestone payments of up to $792 million per program if Jazz advances them into development, along with tiered royalties on future sales.
- Clinical Development Potential: Jazz will hold exclusive worldwide rights to develop and commercialize any resulting antibodies, which is expected to propel potential best-in-class antibody therapies into clinical development, thereby enhancing its market position in oncology.
- Strategic Significance: This collaboration aligns with Jazz's oncology strategy and expands its focus on GI cancers, while AbCellera's T-cell engager platform is set to facilitate the development of novel multispecific antibodies aimed at driving targeted immune activation against hard-to-treat cancers, fostering innovation in immunotherapy.
See More
Jazz Pharmaceuticals and AbCellera Sign $848M Agreement for Antibody Development
- Significant Agreement Value: Jazz Pharmaceuticals has signed an agreement with AbCellera potentially worth up to $848 million, which includes an upfront payment of $56 million and up to $792 million in milestone payments, reflecting strong confidence in next-generation antibody development.
- Focused R&D Objectives: The deal centers on leveraging AbCellera's antibody discovery engine to develop multispecific antibodies targeting gastrointestinal cancers and other solid tumors, aiming to address current treatment gaps and enhance patient options.
- Commitment to Project Advancement: AbCellera is committed to conducting discovery and early-stage research for two programs and initiating a third program within a year, ensuring continuous progress in R&D and strengthening its market competitiveness.
- Commercialization Rights Option: Jazz Pharmaceuticals holds an option for each research program, which, if exercised along with the payment of an option fee, grants exclusive worldwide commercialization rights, providing a crucial safeguard for future revenue growth.
See More
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
- Significant Financial Commitment: The collaboration between Jazz Pharmaceuticals and AbCellera includes $56 million in upfront payments and up to $792 million in potential option fees and milestone payments, reflecting strong confidence in antibody development from both parties.
- Exclusive Development Rights: Jazz has secured exclusive rights to develop and commercialize therapeutic antibodies resulting from the collaboration, which not only enhances its competitive position in oncology but also strategically expands its focus on rare diseases.
- Technological Platform Advantage: AbCellera's T-cell engager platform offers a fully integrated capability from discovery to clinical manufacturing for developing multispecific antibodies for difficult-to-treat cancers, which is expected to significantly improve outcomes compared to existing treatment options.
- Expanded R&D Plans: Under the agreement, AbCellera will conduct discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months, indicating strong potential for long-term collaboration in cancer treatment development.
See More
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
- Collaboration Agreement Details: Jazz Pharmaceuticals has entered into a collaboration with AbCellera involving $56 million in upfront payments and potential option fees and milestone payments totaling up to $792 million, indicating a significant partnership in antibody development.
- Focused Research Direction: The collaboration aims to develop next-generation T-cell engaging multispecific antibodies targeting various gastrointestinal cancers and other solid tumors, aligning with Jazz's strategic focus on rare diseases and enhancing cancer treatment outcomes.
- Technological Platform Advantage: AbCellera's T-cell engager platform offers comprehensive capabilities from discovery to clinical manufacturing, incorporating novel CD3-binding antibodies and multispecific protein engineering technology, which is expected to significantly improve existing cancer treatment efficacy.
- Future Development Potential: The agreement allows Jazz to opt for multiple research programs, which could yield substantial milestone payments and sales royalties for AbCellera, further solidifying its competitive position in the biopharmaceutical market.
See More
Jazz Pharmaceuticals Q1 Earnings Analysis and Investment Recommendations
- Strong Stock Performance: Jazz Pharmaceuticals' stock has risen 37.1% over the past six months, currently trading at $232.44, outperforming the S&P 500 by 28.7%, indicating market recognition of its short-term performance, yet long-term growth potential remains questionable.
- Lackluster Revenue Growth: The company’s annualized revenue growth of 7.5% over the past two years falls short of its five-year trend, suggesting a slowdown in demand that may reflect changing consumer preferences, thereby increasing investment risks.
- Declining Adjusted Operating Margin: Jazz's adjusted operating margin has decreased by 21.5 percentage points over the last five years, currently at 22.4%, raising concerns about its cost structure and failing to achieve expected economies of scale.
- EPS Decline: Despite an 11.7% revenue growth, the company's earnings per share (EPS) has declined by 4.2% annually over the past five years, indicating a weakening profitability per share during its expansion, prompting investors to carefully assess its future earnings potential.
See More
Jazz Pharmaceuticals Unveils New Research Advances at SLEEP 2026
- New Research Findings: Jazz Pharmaceuticals presented 11 late-breaking studies at SLEEP 2026, highlighting Xywav®'s significant efficacy in treating narcolepsy and idiopathic hypersomnia, particularly in improving cardiometabolic risk markers, underscoring the drug's importance in patient health management.
- Personalized Treatment Plans: The research indicates that Xywav's individualized dosing adjustments can be optimized based on patient tolerability and efficacy, with data showing an average time to reach a stable dose of 42.1 days for idiopathic hypersomnia and 41.8 days for narcolepsy, demonstrating the feasibility and effectiveness of personalized treatment.
- Long-term Benefits of Low-Sodium Formulation: New data showcases that Xywav's low-sodium formulation not only alleviates core symptoms but also positively impacts long-term cardiovascular health, with patients reporting significant decreases in cardiovascular risk markers such as non-HDL cholesterol and triglycerides after switching to Xywav, highlighting the clinical benefits of sodium reduction.
- Ongoing Scientific Advancement: Jazz Pharmaceuticals' research team continues to advance the scientific understanding of these rare sleep disorders, emphasizing Xywav's potential to improve patient quality of life and reshape treatment paradigms.
See More
Jazz Pharmaceuticals and AbCellera Collaborate on Antibody Development
- Collaboration Overview: Jazz Pharmaceuticals has entered into a research collaboration and license agreement with AbCellera Biologics to develop next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and other solid tumors, leveraging Jazz's oncology expertise and AbCellera's antibody discovery platform.
- Financial Terms: Under the agreement, AbCellera will receive $56 million in upfront payments for the first two programs and an additional $28 million upon the initiation of the third program, with potential milestone payments of up to $792 million per program if Jazz advances them into development, along with tiered royalties on future sales.
- Clinical Development Potential: Jazz will hold exclusive worldwide rights to develop and commercialize any resulting antibodies, which is expected to propel potential best-in-class antibody therapies into clinical development, thereby enhancing its market position in oncology.
- Strategic Significance: This collaboration aligns with Jazz's oncology strategy and expands its focus on GI cancers, while AbCellera's T-cell engager platform is set to facilitate the development of novel multispecific antibodies aimed at driving targeted immune activation against hard-to-treat cancers, fostering innovation in immunotherapy.
See More
Jazz Pharmaceuticals and AbCellera Sign $848M Agreement for Antibody Development
- Significant Agreement Value: Jazz Pharmaceuticals has signed an agreement with AbCellera potentially worth up to $848 million, which includes an upfront payment of $56 million and up to $792 million in milestone payments, reflecting strong confidence in next-generation antibody development.
- Focused R&D Objectives: The deal centers on leveraging AbCellera's antibody discovery engine to develop multispecific antibodies targeting gastrointestinal cancers and other solid tumors, aiming to address current treatment gaps and enhance patient options.
- Commitment to Project Advancement: AbCellera is committed to conducting discovery and early-stage research for two programs and initiating a third program within a year, ensuring continuous progress in R&D and strengthening its market competitiveness.
- Commercialization Rights Option: Jazz Pharmaceuticals holds an option for each research program, which, if exercised along with the payment of an option fee, grants exclusive worldwide commercialization rights, providing a crucial safeguard for future revenue growth.
See More
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
- Significant Financial Commitment: The collaboration between Jazz Pharmaceuticals and AbCellera includes $56 million in upfront payments and up to $792 million in potential option fees and milestone payments, reflecting strong confidence in antibody development from both parties.
- Exclusive Development Rights: Jazz has secured exclusive rights to develop and commercialize therapeutic antibodies resulting from the collaboration, which not only enhances its competitive position in oncology but also strategically expands its focus on rare diseases.
- Technological Platform Advantage: AbCellera's T-cell engager platform offers a fully integrated capability from discovery to clinical manufacturing for developing multispecific antibodies for difficult-to-treat cancers, which is expected to significantly improve outcomes compared to existing treatment options.
- Expanded R&D Plans: Under the agreement, AbCellera will conduct discovery and early-stage research for two initial programs, with a commitment to start a third program within 12 months, indicating strong potential for long-term collaboration in cancer treatment development.
See More
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
- Collaboration Agreement Details: Jazz Pharmaceuticals has entered into a collaboration with AbCellera involving $56 million in upfront payments and potential option fees and milestone payments totaling up to $792 million, indicating a significant partnership in antibody development.
- Focused Research Direction: The collaboration aims to develop next-generation T-cell engaging multispecific antibodies targeting various gastrointestinal cancers and other solid tumors, aligning with Jazz's strategic focus on rare diseases and enhancing cancer treatment outcomes.
- Technological Platform Advantage: AbCellera's T-cell engager platform offers comprehensive capabilities from discovery to clinical manufacturing, incorporating novel CD3-binding antibodies and multispecific protein engineering technology, which is expected to significantly improve existing cancer treatment efficacy.
- Future Development Potential: The agreement allows Jazz to opt for multiple research programs, which could yield substantial milestone payments and sales royalties for AbCellera, further solidifying its competitive position in the biopharmaceutical market.
See More
